日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study

长效SARS-CoV-2抗体Tixagevimab/Cilgavimab (AZD7442)重复给药的安全性和药代动力学：PROVENT子研究结果

期刊:Clinical Drug Investigation
影响因子:2.7
doi:10.1007/s40261-025-01515-x
Ustianowski, Andrew; Levin, Myron J; De Wit, Stephane; Launay, Odile; Veekmans, Bernard; Rampling, Tommy; Sullivan, James G; Vishnepolsky, Mark; Wijewardane, Priyantha; Fawadleh, Yousef; Zhang, Huixia; Li, Meng; Wickramarachchi, Dilki; Sharbaugh, Audrey; Beavon, Rohini; Thissen, Jesse; Hirao, Lauren; Dzutseva, Vitalina; Seegobin, Seth; Streicher, Katie; Kiazand, Alexandre; Esser, Mark T; Chang, Lee-Jah; Perez, John L; Cohen, Taylor S
SARS-CoV-2
发表日期：2026
文献求助 收藏

Body Mass Index and Vaccine-induced Immune Responses in Children Living With HIV

艾滋病毒感染儿童的体重指数和疫苗诱导的免疫反应

期刊:Pediatric Infectious Disease Journal
影响因子:2.2
doi:10.1097/INF.0000000000005153
Massa, Jacob D; Giganti, Mark J; Lindsey, Jane C; Levin, Myron J; Nachman, Sharon
HIV
炎症/感染
免疫/内分泌
微生物学
发表日期：2026
文献求助 收藏

The recombinant zoster vaccine induces trained immunity in monocytes through persistent downregulation of TGFβ

重组带状疱疹疫苗通过持续下调TGFβ诱导单核细胞产生训练免疫。

期刊:PLoS Pathogens
影响因子:4.9
doi:10.1371/journal.ppat.1013759
Johnson, Michael J; Crotteau, Megan; Ghosh, Debashis; Vu, Thao; Trinity, Luke; Marches, Radu; Ucar, Duygu; Levin, Myron J; Weinberg, Adriana
疱疹
微生物学
单核细胞
细胞生物学
TGFβ
免疫/内分泌
发表日期：2025
文献求助 收藏

The Reduced Immunogenicity of Zoster Vaccines in CMV-Seropositive Older Adults Correlates with T Cell Imprinting

巨细胞病毒血清阳性老年人对带状疱疹疫苗免疫原性降低与T细胞印迹相关

期刊:Vaccines
影响因子:3.4
doi:10.3390/vaccines13040340
Weinberg, Adriana; Vu, Thao; Johnson, Michael J; Schmid, D Scott; Levin, Myron J
T细胞
疱疹
WB
微生物学
T细胞
细胞生物学
免疫/内分泌
发表日期：2025
文献求助 收藏

Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials

AZD7442（Tixagevimab/Cilgavimab）预防有症状COVID-19的疗效、安全性和药代动力学：PROVENT和STORM CHASER试验的15个月最终分析

期刊:Infectious Diseases and Therapy
影响因子:5.3
doi:10.1007/s40121-024-00970-x
Levin, Myron J; Ustianowski, Andrew; De Wit, Stephane; Beavon, Rohini; Thissen, Jesse; Seegobin, Seth; Dey, Kanika; Near, Karen A; Streicher, Katie; Kiazand, Alexandre; Esser, Mark T
发表日期：2024
文献求助 收藏

The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses

儿童和成人细胞培养流感疫苗的经济合理性：成本效益分析综述

期刊:Human Vaccines & Immunotherapeutics
影响因子:3.5
doi:10.1080/21645515.2024.2351675
Fisman, David; Giglio, Norberto; Levin, Myron J; Nguyen, Van Hung; Pelton, Stephen I; Postma, Maarten; Ruiz-Aragón, Jesús; Urueña, Analia; Mould-Quevedo, Joaquin F
微生物学
Cell Culture
细胞生物学
流感
发表日期：2024
文献求助 收藏

Absenteeism and Productivity Loss Due to Influenza or Influenza-like Illness in Adults in Europe and North America

欧洲和北美成年人因流感或流感样疾病导致的缺勤和生产力损失

期刊:Diseases
影响因子:3
doi:10.3390/diseases12120331
Fisman, David; Postma, Maarten; Levin, Myron J; Mould-Quevedo, Joaquin
微生物学
流感
发表日期：2024
文献求助 收藏

AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019

AZD7442（Tixagevimab/Cilgavimab）用于2019冠状病毒病症状暴露后预防

期刊:Clinical Infectious Diseases
影响因子:7.3
doi:10.1093/cid/ciac899
Levin, Myron J; Ustianowski, Andrew; Thomas, Steven; Templeton, Alison; Yuan, Yuan; Seegobin, Seth; Houlihan, Catherine F; Menendez-Perez, Ibrahim; Pollett, Simon; Arends, Rosalinda H; Beavon, Rohini; Dey, Kanika; Garbes, Pedro; Kelly, Elizabeth J; Koh, Gavin C K W; Ivanov, Stefan; Near, Karen A; Sharbaugh, Audrey; Streicher, Katie; Pangalos, Menelas N; Esser, Mark T
微生物学
发表日期：2023
文献求助 收藏

Predictors of 5-Year Persistence of Antibody Responses to Zoster Vaccines

预测带状疱疹疫苗抗体反应持续5年的因素

期刊:Journal of Infectious Diseases
影响因子:4.5
doi:10.1093/infdis/jiad132
Weinberg, Adriana; Scott Schmid, D; Leung, Jessica; Johnson, Michael J; Miao, Congrong; Levin, Myron J
微生物学
疱疹
发表日期：2023
文献求助 收藏

Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants

PROVENT预防试验中突破性SARS-CoV-2感染与AZD7442（Tixagevimab/Cilgavimab）耐药变异株无关

期刊:Journal of Infectious Diseases
影响因子:4.5
doi:10.1093/infdis/jiad210
Tuffy, Kevin M; Ahani, Bahar; Aksyuk, Anastasia A; Avila, Miles; Brady, Tyler; Kijak, Gustavo H; Koh, Gavin; Levin, Myron J; Roe, Tiffany L; Schuko, Nicolette; Thissen, Jesse; Ustianowski, Andrew; Zhang, Tianhui; Kelly, Elizabeth J; Streicher, Katie
SARS-CoV-2
炎症/感染
发表日期：2023
文献求助 收藏